Gilead Sciences: Best Large-Cap Biotech Pick For 2013
Posted on December 28, 2012 at 15:10 PM EST
Gilead Sciences, Inc. (NASDAQ: GILD) is one of the best large-cap idea in the biotech space because it's the only growth story that has earnings potentially doubling in the next 4 years from $4 in 2013 to at least $8 in 2016, driven by GS-7977 sales and conservative margins. [More...]